Chronic Kidney Disease Treatment
Chronic Kidney Disease Treatment
The honest framing first: kidney function that has been lost does not come back, and this disease is managed rather than cured. What treatment can change is how fast the remaining function is lost, how many complications arrive along the way, and whether the transition to dialysis or transplantation is planned on a person's own timetable or forced by a crisis. This page takes those in order — the measures that slow the slope, the medicines that do most of the work, the complications that are treated rather than endured, and the two forms of kidney replacement.
What slows it, and what only looks like it does
Because the disease is defined by a slope, the measure of any treatment is whether it changes the slope. Four things do, and they do so independently of one another, which is why they are pursued together rather than chosen between.
| Measure | What it does | Why it works |
|---|---|---|
| Blood pressure to target | The strongest single lever on the rate of decline | The filtering units are a high-pressure system, and they are being damaged by the pressure as much as by the original disease |
| Reducing the protein leak | Both slows decline and lowers cardiovascular risk | Protein crossing the filter is itself toxic to it; less leak means less of the inflammation and scarring that follows |
| Glucose control in diabetes | Prevents further vascular damage and buys time | Years of raised glucose are what produced the damage; the same mechanism continues until it is addressed |
| Removing ongoing injury | Stops an added, superimposed decline | Nephrotoxic medicines, obstruction, recurrent dehydration and infection each add their own loss on top of the chronic one |
Two things are worth stating plainly, because patients ask about both. Dietary protein restriction is real but modest and is individualised rather than applied by rule — severe restriction risks malnutrition, which is its own harm. And "kidney cleanses", herbal preparations and commercial detox programmes have no evidence behind them; several contain potassium or compounds that are actively dangerous to an impaired kidney. Anything taken for the kidneys should be declared to the treating team, because "natural" and "safe for the kidney" are not the same claim.
The medicines that do most of the work
Two families of medicine carry most of the benefit in chronic kidney disease, and both were originally designed for blood pressure — their kidney protection turned out to be partly independent of the pressure they lower.
ACE inhibitors and angiotensin receptor blockers relax the vessel that leaves the filtering unit, lowering the pressure inside it. That pressure is what drives protein across the filter, so lowering it reduces the leak, and reducing the leak slows the scarring. They are used in most patients with significant albuminuria whether or not blood pressure is high, and they are introduced with a creatinine check shortly afterwards, because a small early rise in creatinine is expected and is not a reason to stop — a large one is a reason to look for a second problem such as a narrowed artery or dehydration.
SGLT2 inhibitors were developed for diabetes and turned out to protect the kidney in several forms of disease, including forms without diabetes. They lower pressure inside the filtering unit by a different mechanism, and the trials behind them showed slower decline and fewer hospital admissions for heart failure and kidney failure. Like the first group, they are introduced with monitoring and explained rather than simply added.
Beyond these two, treatment is aimed at what the individual patient carries: glucose control using agents chosen for their kidney and heart profile; statins for cardiovascular risk, which in this disease is substantial; bicarbonate where the blood has become acid; and phosphate binders, vitamin D and the medicines that manage bone and mineral disease once those changes appear. Each has a reason and a monitoring schedule, and a written list of what each is for is one of the most useful documents a patient can carry.
Treating the complications rather than enduring them
Most of what makes advanced kidney disease miserable is not the filtration number but its consequences — and several of them respond well once identified. This is the part of treatment with the fastest visible payoff.
Anaemia. The kidney makes less of the hormone that drives red cell production. Treated with iron where stores are low and with agents that replace the hormone where they are not, it restores energy and exercise capacity that patients had quietly assumed were gone for good.
Bone and mineral disease. As function falls, phosphate accumulates and calcium and vitamin D handling changes, pulling calcium out of bone. Managed with dietary phosphate advice, binders and vitamin D, it protects the skeleton and the blood vessels together, because the same chemistry calcifies both.
Fluid and salt. Retention produces swelling, breathlessness and high blood pressure. Salt restriction is the first move and is more effective than most patients expect; diuretics are added where needed.
Acidosis and potassium. Both are silent until advanced. Both are managed — bicarbonate supplementation for the first, dietary advice and medicines for the second — and potassium is the one that can become dangerous quickly, which is why it is measured rather than assumed.
Itching, cramps and sleep. Less glamorous, and often the symptoms that patients most want relief from. They respond partly to correcting the chemistry and partly to straightforward symptomatic measures, and they are worth raising at every visit rather than tolerating.
Dialysis: two forms, and a choice about a life
Dialysis replaces part of what the kidneys do — clearing waste, removing fluid, correcting the chemistry — and it does not replace all of it, which is why medicines and diet continue alongside. There are two established forms, and the difference between them is mainly about where a person wants their treatment to happen.
| Form | How it works | What it asks of the patient |
|---|---|---|
| Haemodialysis | Blood is circulated through a machine that filters it, then returned; typically three sessions a week in a unit | Attendance on a fixed schedule, and a vascular access — a fistula or graft — created in advance and looked after daily |
| Peritoneal dialysis | Fluid is placed into the abdomen through a catheter and the abdominal lining filters the blood across it; usually done at home, daily | Strict sterile technique every day, and storage space and a clean area at home. In exchange: independence, and far easier travel |
| Hybrid and intensified approaches | Longer or more frequent haemodialysis sessions, or haemodiafiltration, which combines diffusion with convection | More time on the machine; chosen where the standard schedule does not control the chemistry or the fluid well |
Our department runs a haemodialysis unit with 20 specialised beds, more than 30 Fresenius haemodialysis machines, haemodiafiltration machines and 2 CRRT machines, supported by a secondary reverse osmosis water treatment system, a centralised fluid supply system and a haemodialysis information management system. It also places peritoneal dialysis catheters and establishes and maintains vascular access, and it performs double plasma exchange and hybrid blood purification where the indication calls for them.
Two points of timing matter more than any of the technology. The first is that vascular access and catheter placement are done in advance — a fistula needs weeks to mature, and a catheter placed in an emergency is a worse start than one placed on a plan. The second is that dialysis is begun on symptoms and chemistry as well as on a number, so starting a little later when someone is well is often better than starting early on a threshold alone.
Transplantation, and what the assessment involves
Where it is possible, transplantation restores more normal life than dialysis can: no schedule, no machine, fewer dietary restrictions, and better long-term survival for most recipients. Whether it is possible is a question of assessment rather than of preference, and the assessment is begun early because it takes time.
It covers four areas. Whether the original disease can recur in a new kidney, and whether the underlying condition is stable enough for surgery. Whether the heart and blood vessels will tolerate the operation and the medicines after it, since cardiovascular disease is common in this group. Whether there is active infection or a cancer risk that would make immune suppression unsafe. And, most practically, where a kidney would come from — a living donor, whom the patient may already have in mind, or a deceased donor through the allocation system of the country where the transplant would take place, with its own rules and waiting times.
The last point is the one international patients most need stated plainly. Transplant eligibility, donor rules, waiting times and funding are national arrangements, and they differ substantially between countries. A transplant assessment conducted here establishes whether a patient is medically suitable and what the next steps would be; it does not by itself place anyone on another country's list. Patients should discuss candidacy with their own nephrology team as well, because the transplant that happens is usually the one coordinated with the system the patient will actually be treated in.
What treatment actually asks of a person
Taken together, treatment for chronic kidney disease is less a course than a regimen: measurements at intervals, medicines whose doses move with the chemistry, dietary advice that changes as the stage changes, and one decision — about replacement therapy — prepared over years rather than taken in a crisis.
The part that patients control, and the part that matters more than most realise, sits in three places. Taking the blood pressure medicines consistently, even when the pressure is normal, because their protective effect is not only about the reading. Avoiding the medicines that harm the kidney — particularly anti-inflammatory painkillers — and asking about anything new before starting it, including supplements and herbal products. And keeping the appointments and the measurements, because the trend is the only thing that reveals whether the plan is working, and it cannot be reconstructed from memory.
What treatment does not ask is that a person stop living. Dialysis can be arranged while travelling, work and family plans are compatible with every stage up to the advanced ones, and the transition to replacement therapy is best prepared while there is still time to choose. That preparation — started at G4, discussed openly, and written down — is the single thing that most changes what the later years of this disease are like.